CO6541638A2 - Combinaciones terapéuticas de teobromina y una antihistamina - Google Patents

Combinaciones terapéuticas de teobromina y una antihistamina

Info

Publication number
CO6541638A2
CO6541638A2 CO12098529A CO12098529A CO6541638A2 CO 6541638 A2 CO6541638 A2 CO 6541638A2 CO 12098529 A CO12098529 A CO 12098529A CO 12098529 A CO12098529 A CO 12098529A CO 6541638 A2 CO6541638 A2 CO 6541638A2
Authority
CO
Colombia
Prior art keywords
theobromine
antihistamine
therapeutic combinations
therapy
separately
Prior art date
Application number
CO12098529A
Other languages
English (en)
Spanish (es)
Inventor
John Brew
Robin Mark Bannister
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of CO6541638A2 publication Critical patent/CO6541638A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CO12098529A 2009-12-14 2012-06-12 Combinaciones terapéuticas de teobromina y una antihistamina CO6541638A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0921803.3A GB0921803D0 (en) 2009-12-14 2009-12-14 Drug composition and its use in therapy

Publications (1)

Publication Number Publication Date
CO6541638A2 true CO6541638A2 (es) 2012-10-16

Family

ID=41667043

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12098529A CO6541638A2 (es) 2009-12-14 2012-06-12 Combinaciones terapéuticas de teobromina y una antihistamina

Country Status (17)

Country Link
EP (1) EP2512472A1 (uk)
JP (2) JP2013513652A (uk)
CN (1) CN102802625A (uk)
AU (1) AU2010332495C1 (uk)
BR (1) BR112012014159A8 (uk)
CA (1) CA2784215A1 (uk)
CO (1) CO6541638A2 (uk)
GB (1) GB0921803D0 (uk)
IL (1) IL220384A0 (uk)
MX (1) MX2012006624A (uk)
NZ (1) NZ600267A (uk)
PE (1) PE20121538A1 (uk)
RU (1) RU2012129675A (uk)
SG (2) SG181603A1 (uk)
UA (1) UA105827C2 (uk)
WO (1) WO2011073647A1 (uk)
ZA (1) ZA201204294B (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
GB0910375D0 (en) 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
CN103263533B (zh) * 2013-05-31 2014-11-05 杨宏伟 一种治疗咳嗽的可可碱组合物及其用途及其制剂
CN104188998A (zh) * 2014-09-18 2014-12-10 中山大学 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂
CN104224819B (zh) * 2014-09-18 2016-08-17 中山大学 一种柚皮苷与盐酸左西替利嗪药物组合物及其制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE59550T1 (de) * 1986-04-17 1991-01-15 Alza Corp Chlorpheniramine therapie.
HUP9700654A2 (hu) 1997-03-26 1999-09-28 Dezső Korbonits Teobromin tartalmú köhögéscsillapító készítmények
JPH10316568A (ja) * 1997-05-13 1998-12-02 Taisho Pharmaceut Co Ltd 医薬組成物
JP2003012514A (ja) * 2001-07-02 2003-01-15 Taisho Pharmaceut Co Ltd 医薬組成物
JP2003128549A (ja) * 2001-08-15 2003-05-08 Rohto Pharmaceut Co Ltd 粘膜適用組成物
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis

Also Published As

Publication number Publication date
JP6078605B2 (ja) 2017-02-08
EP2512472A1 (en) 2012-10-24
RU2012129675A (ru) 2014-01-27
AU2010332495C1 (en) 2016-02-11
AU2010332495A1 (en) 2012-06-21
IL220384A0 (en) 2012-08-30
MX2012006624A (es) 2012-10-05
SG10201408374WA (en) 2015-01-29
BR112012014159A8 (pt) 2017-12-26
JP2013513652A (ja) 2013-04-22
CA2784215A1 (en) 2011-06-23
WO2011073647A1 (en) 2011-06-23
PE20121538A1 (es) 2012-12-21
ZA201204294B (en) 2013-02-27
GB0921803D0 (en) 2010-01-27
SG181603A1 (en) 2012-07-30
AU2010332495B2 (en) 2015-01-22
UA105827C2 (uk) 2014-06-25
CN102802625A (zh) 2012-11-28
NZ600267A (en) 2013-07-26
BR112012014159A2 (pt) 2017-08-29
JP2016040280A (ja) 2016-03-24

Similar Documents

Publication Publication Date Title
CO6541638A2 (es) Combinaciones terapéuticas de teobromina y una antihistamina
EP3052476A4 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
SMT201600430B (it) Inibitori di chinasi e loro uso nel trattamento del cancro
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
CL2014002754A1 (es) Forma de dosis de liberación controlada solida que comprende un nucleo con una primera porcion de un analgesico opioide y una cubierta que encierra el nucleo y comprende una segunda porcion del analgesico opioide; metodo de preparacion; uso en el tratamiento del dolor. (divisional de solicitud n°1450-2014).
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
EP3082423A4 (en) Cancer treatments using combinations of cdk and erk inhibitors
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
BRPI1011505A2 (pt) formas de pró-drogas de inibidores de quinase e sua aplicação em terapia
CL2015000294A1 (es) Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.
DOP2015000183A (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
EP2262777B8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1
CL2015000375A1 (es) Composicion farmaceutica en forma de microparticulas que comprende un nucleo inerte y al menos una primera capa de principio activo; proceso de formacion de microparticulas; combinacion farmaceutica; kit farmaceutico; uso para tratar y/o prevenir edemas, enfermedades cardiovasculares, diabetes, hipertension, entre otras.
BR112012004720A2 (pt) inibidores de cinase, formas de profármaco dos mesmos e seu uso em terapia
HK1198031A1 (zh) 有用於治療濫用藥物及酒精的 衍生物
CO6700840A2 (es) Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia
AR082215A1 (es) Composicion farmaceutica agradable al paladar
UA108993C2 (uk) Лікарська комбінація з теоброміном і її застосування у лікуванні кашлю
CO6541630A2 (es) Combinación teobromina con un descongestivo y su uso para el tratamiento de la tos
BRPI0920878A2 (pt) inbidor de ksp161 para aumentar apoptose, sua administração e seu uso.
DK2050435T3 (da) Hostepræparat
BR112012011224A2 (pt) teobromina e agente combinado com um opióide antitussígeno e seu uso terapêutico
WO2011056604A3 (en) Treatment of sunburn using analgesics and antihistamines
UY33789A (es) Combinación que comprende un derivado de la familia de las combretastatinas y cetuximab
ECSP12011969A (es) Combinaciones terapéuticas de teobromina y una antihistamina